CDH6 recombinant proteins and antibodies

Cadherin 6 (CDH6), also known as fetal kidney cadherin or K-cadherin, is a protein encoded by the CDH6 (also known as CAD6 or KCAD) gene. CDH6 is a single-pass transmembrane protein, a type II classical cadherin, and a member of the cadherin superfamily. CDH6 is involved in the morphogenesis and development of the embryonic kidney and drives the mesenchymal-epithelial differentiation required for kidney morphogenesis, but in the adult kidney, the expression of CDH6 is very weak. In normal tissues of adults, the expression of CDH6 is limited to the renal tubules, bile duct epithelial cells, etc. of the kidney. In addition, CDH6 is also expressed in platelets and plays a functional role in platelet aggregation and thrombosis. This function is mediated by the binding of the RGD motif to the αIIbβ3 integrin, which undergoes conformational changes and binds to fibrinogen, thereby cross-linking platelets. More about CDH6 structure and function >>

According to reports, CDH6 is highly expressed in thyroid cancer, gastric cancer, pancreatic cancer and ovarian cancer. Among them, renal cancer is the first cancer to be found to have high CDH6 expression. At the same time, combined with its limited expression in normal tissues, CDH6 has also become an optional target for the development of targeted drugs. Although there are currently only three pharmaceutical companies in the world that have deployed CDH6, all of which are CDH6 ADCs, candidate products have shown great potential.

In order to accelerate the development of CDH6 biotherapeutics, DIMA BIOTECH has prepared a full range of CDH6 target products (active proteins, reference antibodies, and flow cytometry-validated monoclonal antibodies), and also provides a number of customized services, including customized services for multiple genus protein antibodies, antibody humanization, and affinity maturation services. In addition, DIMA BIOTECH has also prepared a CDH6 target single B cell seed library, and lead antibody molecules can be obtained in as fast as 28 days; at the same time, we have currently screened out 26 CDH6 lead molecules, all of which are human-monkey cross-molecules, and customers can get the molecules for functional evaluation and verification the next day; for some molecules, we are also conducting ADC endocytosis activity and killing verification, and please inquire for specific data.